

Supplementary information S1 (table) | Description of genes regulated by p53 (part I)*

#	Gene Name(s)	Short Description	Accession #	1st Half-site	Spacer	2nd Half-site	Refs
1	ABCB1, MDR1	ATP-binding cassette sub-family B member 1	AF016535	GGGCAGGAACA	gcgccgggct	GGGCTGAGCA	1
2	ACTA2	smooth muscle alpha-actin	NM_001613	AACCATGCCT		GCATCTGCC	2
3	AIFM2, AMID	apoptosis-inducing factor, mitochondrion-assoc.	NM_032797	AGGCATGAGC	caccgtgcct	GGCCATGCC	3
3	AIFM2, AMID	apoptosis-inducing factor, mitochondrion-assoc.	NM_032797	AGGTCTCGCTA	tggtgccc	AGGCTGGTCT	3
4	ANLN	anillin, actin binding protein	NM_018685	GAACTGGCTT	ttctga	GGCCAGGCC	4
5	APAF1	apoptotic peptidase activating factor 1	NM_001160	AGACATGTCT	ggagaccctagga	CGACAAGCCC	5
6	APC	adenomatosis polyposis coli	NM_000038	GGGCATACCC	ccgaggggtacg	GGGCTAGGGCt	6
7	ARID3A, E2FBP1	AT rich interactive domain 3A (BRIGHT-like)	NM_005224	GGACACGCTG		GGACATGCCT	7
8	ATF3	activating transcription factor 3	NM_001674	AGTCATGCCG	ctggcttggcaccatt	GGTCATGCCT	8
9	BAI1	brain-specific angiogenesis inhibitor 1	NM_001702	tGGCTGCCT		GGACATGTTC	9
10	BAX	BCL2-associated X protein	NM_004324	GGGCAGGCC		GGGCTTGTCG	10
11	BBC3, PUMA	BCL2 binding component 3	NM_014417	CTGCAAGTCC		TGACTTGTC	11
12	BCL2L14, BCL-G	BCL2-like 14 (apoptosis facilitator)	NM_030766	AGCCAAGGCT		GGTCTTGAAC	12
13	BCL6	B-cell CLL/lymphoma 6 (zinc finger protein 51)	NM_001706	AGACAGTGCTT	gggggtgattc	GGGCTAGTCT	13
14	BDKRB2, BK2	bradykinin receptor B2	NM_000623	GGAagTGCCC		AGGagcTga	14
15	BID	BH3 interacting domain death agonist	NM_197966	GGGCATGATG		GTGCATGCCT	15
16	BIRC5, survivin	baculoviral IAP repeat-containing 5 (survivin)	NM_001168	GGGCGTGCGC	tcc	CGACATGCC	16
17	BNIP3L	BCL2/adenovirus E1B interacting protein 3-like	NM_004331	AAGCTAGTCT	cagtg	GcGCATGCCT	17
18	BTG2, TIS21	BTG family, member 2	NM_006763	AGTCCGGGCA	g	AGCCCAGCA	18
19	C12orf5	chromosome 12 open reading frame 5	NM_020375	AGACATGTCC	ac	AGACTTGCT	19
20	C13orf15, RGC32	chromosome 13 open reading frame 15	NM_014059	AGGCgAGTTT	aag	cAGCTTGTC	20
21	CASP1	caspase 1, apoptosis-related cysteine peptidase	NM_033292	AGACATGCAT		ATGCATGCa	21
22	CASP10	caspase 10, apoptosis-related cys-peptidase	NM_032977	AAACTTGCTg	gttta	AAcTTGgCT	22
23	CASP6	caspase 6, apoptosis-related cysteine peptidase	NM_001226	AGGCAAGGAG	tttg	AGACAAGTCT	23
24	CAV1	caveolin 1, caveolae protein, 22kDa	NM_001753	GCCCAAGCAC	cccagcgcg	GGAGAAcGTTC	24
25	CCNG1	cyclin G1	NM_004060	GcACAAGCCC		AGGCTAGTCC	25
26	CCNK	cyclin K	NM_003858	AAACTAGCTT	gc	AGACATGCTg	26
27	CD82, KAI1	CD82 molecule	NM_002231	AGGCAAGCT	ggggca	GctCAAGCCT	27
28	CDC25C	cell division cycle 25 homolog C (S. pombe)	NM_001790	GGGCAAGTCT	taccattcca	GAGCAAGCaC	28
29	CDKN1A, p21	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	NM_000389	AGACTGGGCA		TGTCTGGGCA	29
29	CDKN1A, p21	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	NM_000389	GAAgAAGaCT		GGGCATGTCT	30
29	CDKN1A, p21	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	NM_000389	GAACATGTCC		cAACATGTTg	30

30	Chmp4C	chromatin modifying protein 4C	NM_152284	AAACAAGCCC	agtagcagcagctgctcc	GAGCTTGCCC	31
31	COL18A1	collagen, type XVIII, alpha 1	NM_030582	TGACATGTGT		GAGCATGTAT	12
31	COL18A1	collagen, type XVIII, alpha 1	NM_030582	TGACATGTGT		GAGCATGTAT	12
32	CRYZ	crystallin, zeta (quinone reductase)	NM_001889	ctGCAAGTCC	att	AAACcTGTTT	4
33	CTSD, IRDD	cathepsin D	NM_001909	AAcCTTGgTT		tgcAAgAgGCTT	32
33	CTSD, IRDD	cathepsin D	NM_001909	AAGCTgGgCC		GGGCTgaCCC	32
34	CX3CL1, fractalkine	chemokine (C-X3-C motif) ligand 1	NM_002996	GGGCATGTTC	c	CAGCTGTGG	33
35	DDB2	damage-specific DNA binding protein 2, 48kDa	NM_000107	GAACAAGCCC	t	GGGCATGTTT	34
36	DDIT4, REDD1	DNA-damage-inducible transcript 4	NM_019058	AAACAAGTCT		TTCCTTGATC	35
37	DDR1	discoidin domain receptor family, member 1	NM_013994	GAGCTGGTCC		AGGCTTATCT	36
38	DKK1	dickkopf homolog 1 (<i>Xenopus laevis</i>)	NM_012242	AGCCAAGCTT	ttaatg	AACCAAGTTC	37
39	DNMT1	DNA (cytosine-5-)-methyltransferase 1	NM_001379	GCGCATGCGT	gttccct	GGGCATGGCC	38
40	DUSP1, MKP1	dual specificity phosphatase 1	NM_004417	GGTCCTGCC	a	GGCAAATGGG	39
41	DUSP5	dual specificity phosphatase 5	NM_004419	CAACAAGCCC	t	TGTCTAGTGC	40
42	EDN2	endothelin 2	NM_001956	CTGCAAGCCC		GGGCATGCC	41
43	EEF1A1	eukaryotic translation elongation factor 1 alpha 1	NM_001402	GGGCAGACCC	ga	GAGCATGCC	42
43	EEF1A1	eukaryotic translation elongation factor 1 alpha 1	NM_001402	GGACACGTAG	attc	GGGCAAGTCC	42
43	EEF1A1	eukaryotic translation elongation factor 1 alpha 1	NM_001402	AAACATGATT	ac	AGGGACATCT	42
44	EGFR	epidermal growth factor receptor	NM_005228	GAGCTAGACG	tcc	GGGCAGCCCC	43
45	EphA2	EPH receptor A2	NM_004431	CACCATGTTG	gcc	AGGCATGTCT	44
46	FANCC, FAC	Fanconi anemia, complementation group C	NM_000136	GGACATGTTT	aaatacttga	GAGCTATTTT	45
47	FAS, CD95	Fas (TNF receptor superfamily, member 6)	NM_000043	GGACAAGCCC		TGACAAGCCA	46
48	FDXR	ferredoxin reductase	NM_024417	GGGCgAgGagC		GGGCTTGCCC	47
49	GADD45A	growth arrest and DNA-damage-inducible, alpha	NM_001924	GAACATGTCT		AAGCATGCTG	48
50	GDF15, MIC-1	growth differentiation factor 15	NM_004864	AGCCATGCC		GGGCAAGAAC	49
50	GDF15, MIC-1	growth differentiation factor 15	NM_004864	CATCTTGCCC		AGACTTGCT	50
51	GML	GPI anchored molecule like protein	NM_002066	AtGCTTGCCC		AGGCATGTCC	51
52	GPX1	glutathione peroxidase 1	NM_000581	GGGCCAGACC		AGACATGCCT	19
53	HBV	hepatitis B virus	get_this	TTGCATGTAT	acaagct	AAACAGGCTT	52
54	HD, Huntington	huntingtin (Huntington disease)	NM_002111	ATGCTTGTTT	tacagaa	GAGCATGTTA	53
54	HD, Huntington	huntingtin (Huntington disease)	NM_002111	CGCCATGTTG	gcc	AGGCTGGTCT	53
54	HD, Huntington	huntingtin (Huntington disease)	NM_002111	GGGCCTGCTT	ccagtt	AAGCTTGCTT	53
55	HGF, SF	hepatocyte growth factor	NM_000601	ACACATGTAT		TTTCTGTTT	54
56	HIC1	hypermethylated in cancer 1	NM_006497	GGGCGCTGCC		TGGCACAGCTC	55
57	HRAS, c-Ha-Ras	Harvey rat sarcoma viral oncogene homolog	NM_176795	large	cluster	site	56

58	HSP90AB1, hsp90beta	heat shock protein 90kDa alpha B 1	NM_007355	GGGACTGTCT	gggtatcgga	AAGCAAGCCT	57
59	HSPA8	heat shock 70kDa protein 8	NM_006597	GcACTAGTTC	tggaacct	GcGCgTGCTT	4
60	IBRDC2, p53RFP	IBR domain containing 2	NM_182757	AGACAGGTCC		TGACAAGCAG	58
61	IER3, IEX-1	immediate early response 3	NM_003897	GCCACATGCCT		CGACATGTGCC	59
62	IGFBP3	insulin-like growth factor binding protein 3	NM_000598	large	cluster	site	60
62	IGFBP3	insulin-like growth factor binding protein 3	NM_000598	GGGCAAGACC		TGCCAAGCCT	60
62	IGFBP3	insulin-like growth factor binding protein 3	NM_000598	AAACAAGCCA	c	CAACATGCTT	60
63	IRF5	interferon regulatory factor 5	NM_032643	AGGCATGCCa	ca	AGGCATGgTC	61
64	KRT8, CK8	keratin 8	NM_002273	ccGCcTGCCT	cc	ActCcTGCCT	62
65	LGALS3, galectin-3	lectin, galactoside-binding, soluble, 3	NM_002306	GGGCTTGCAA	gctg	GAGCCTTGTTT	63
66	LIF	leukemia inhibitory factor	NM_002309	GGACATGTCCG		GGACAGCTC	64
67	LRDD, PIDD	leucine-rich repeats and death domain containing	NM_018494	AGGCcTGCCT	gcgtgctg	GGACATGTCT	65
68	MAD1L1, MAD1	MAD1 mitotic arrest deficient-like 1 (yeast)	NM_003550	GATTCAAGCTG		ATACTGAGT	66
69	mdm2	Mdm2, transformed 3T3 cell double minute 2	NM_002392	AGTTAAGTCC		TGACTTGCT	67
69	mdm2	Mdm2, transformed 3T3 cell double minute 2	NM_002392	GGTCAAGTTC		AGACACGTTc	67
70	MET	met proto-oncogene	NM_000245	ggaeggacag	cacgcgaggcagac	AGACAcGTgC	68
71	MLH1	mutL homolog 1, colon cancer	NM_000249	AGGCATGTAC	a	GCGCATGCCC	69
72	MMP2	matrix metalloproteinase 2	NM_004530	AGACAAGCCT		GAACCTGTCT	70
73	MSH2	mutS homolog 2	NM_000251	GAcCTAGgCg	c	AGGCATGCgC	71
73	MSH2	mutS homolog 2	NM_000251	AGGCTAGTTT	ttttttgttttc	AAGTTTCCTT	72
74	NDRG1	N-myc downstream regulated gene 1	NM_006096	CCACATGCAC	acgcacgagcgc	GCACATGAAC	73
75	NLRC4, Ipaf	NLR family, CARD domain containing 4	NM_021209	AGACATGTTC		CTGGTAGTTT	74
76	NOS3	nitric oxide synthase 3 (endothelial cell)	NM_000603	GAGCcTcCCa	gcc	GGGCTTGTTc	75
77	ODC1	ornithine decarboxylase 1	NM_002539	GGACcAGTTC	caggc	GGGcAGaCC	4
77	ODC1	ornithine decarboxylase 2	NM_002539	GGGCTcGCCT	tggtacagac	GAGCggGCCC	4
78	P2RXL1	purinergic receptor P2X-like 1, orphan receptor	NM_005446	GAACAAGggC	at	GAGCTTGCT	76
79	P53AIP1	p53-regulated apoptosis-inducing protein 1	NM_022112	TCTCTTGCCC		GGGCTTGTCG	77
80	PCBP4, MCG10	poly(rC) binding protein 4	NM_020418	GgtCTTGgCCC		AGACTTAGCaC	78
80	PCBP4, MCG10	poly(rC) binding protein 4	NM_020418	GAACTT	aagaccgagcctct	GGACAAGTT	78
81	PCNA	proliferating cell nuclear antigen	NM_002592	GAACAAGTCC		GGGCATaTgT	79
82	PERP	PERP, TP53 apoptosis effector	NM_022121	AGGCAAGCTC		CAGCTTGTTc	80
83	PLAGL1, ZAC	pleiomorphic adenoma gene-like 1	BC074814	CAACTAGACT		AGACTAGCTT	81
84	PLK2, SNK	polo-like kinase 2 (Drosophila)	NM_006622	AGACATGgTg	tgt	AAACTAGCTT	82
84	PLK2, SNK	polo-like kinase 2 (Drosophila)	NM_006622	GGtCATGaTT	cct	tAACTTGCCCT	82
84	PLK2, SNK	polo-like kinase 2 (Drosophila)	NM_006622	AAACATGCCT		GGACTTGCCC	82

85	PLK3	polo-like kinase 3 (Drosophila)	NM_004073	TAACATGCCC	gggcaa	AAGCGAGCGC	19
86	PML	promyelocytic leukemia	NM_002675	GcGCTgGCCT	ggagccag	GGGCATGTCC	83
87	PMS2	PMS2 postmeiotic segregation increased 2	NM_000535	ATACTTGATT	tg	TTTCTTGATA	69
88	PPM1J, MGC19531	protein phosphatase 1J (PP2C domain containing)	NM_005167	GAACATGCCT		GAGCAAGCCC	41
89	PRDM1, BLIMP1	PR domain containing 1, with ZNF domain	NM_182907	GTGCAAGTCT		GGACATGTTT	84
90	PRKAB1, AMPKbeta1	protein kinase, AMP-activated, beta 1	NM_006253	GTTCTTGCCG		CGGCTTGCCCT	19
91	PTEN	phosphatase and tensin homolog	NM_000314	GAGCAAGCCC	caggcagctacact	GGGCATGCTC	85
92	PTK2, FAK	PTK2 protein tyrosine kinase 2	NM_153831	AAGCAAGCC		no 2nd site	86
93	PYCARD, ASC	PYD and CARD domain containing	NM_013258	GTGCAAGCCC	ag	AGACAAGCAC	87
94	RABGGTA	Rab geranylgeranyltransferase, alpha subunit	NM_004581	CCTCTGTGG	aacgtgca	AAGCCTGTCC	19
95	RB1	retinoblastoma 1 (including osteosarcoma)	NM_000321	GGGCGTGCCC	cgac	GTGCgcGCgC	88
96	RFWD2, COP1	ring finger and WD repeat domain	NM_022457	AGACTTGCCCT	gt	GAACAGTCAC	89
97	RPS27L	ribosomal protein S27-like	NM_015920	GGGCATGTAG		TGACTTGCCC	41
98	RRM2B, p53R2	ribonucleotide reductase M2 B	NM_015713	tGACATGCCC		AGGCATGTCT	90
99	S100A2	S100 calcium binding protein A2	NM_005978	GGGCATGTgT		GGGCAcGTTC	91
100	SCARA3, CSR1	scavenger receptor class A, member 3	NM_016240	GGGCAAGCCC		AGACAAGTTg	92
101	SCD	stearoyl-CoA desaturase (delta-9-desaturase)	NM_005063	GGGCcgGTCC	t	GGGCTAGgCT	4
102	SCN3B	sodium channel, voltage-gated, type III, beta	NM_018400	TGACTTGCTC		TGCCTTGCTC	93
102	SCN3B	sodium channel, voltage-gated, type III, beta	NM_018400	TGGCAAGGCT		GAGCTAGTTC	93
103	SERPINB5, maspin	serpin peptidase inhibitor, clade B, member 5	NM_002639	GAACATGTTg	g	AGGCcTtTTg	94
104	SERPINE1	serpin peptidase inhibitor, clade E, member 1	NM_000602	AcACATGCCT		cAGCAAGTCC	95
105	SESN1, PA26	sestrin 1	AF033120	GGACAAGTCT		CCACAAGTCa	96
106	SFN, 14-3-3sigma	stratifin	NM_006142	AGCATTAGCCC		AGACATGTCC	97
107	SH2D1A, SAP	SH2 domain protein 1A, Duncan's disease	NM_002351	GGCTGGCTC	agetgt	CAGCTTGCTT	98
107	SH2D1A, SAP	SH2 domain protein 1A, Duncan's disease	NM_002351	GGGCTGGCTC		GGCTGGCTC	98
107	SH2D1A, SAP	SH2 domain protein 1A, Duncan's disease	NM_002351	CAACACTGCAC	tagt	GGGCTGGCTC	98
108	SLC38A2	solute carrier family 38, member 2	NM_018976	AAcCATGCTg	ttacacgcacc	AGCTTGTC	4
109	STEAP3, TSAP6	STEAP family member 3	NM_001008410	AGACAAGCAT	ag	GGACATGCTC	99
110	TAP1	transporter 1, ATP-binding cassette	NM_000593	GGGCTTGgCC	ctgccc	GGACTTGCCCT	100
111	TGFA	transforming growth factor, alpha	NM_003236	GGGCAGGCC		TGCCTAGTCT	101
112	TNFRSF10A, DR4	tumor necrosis factor receptor superfamily, 10a	NM_003844	GGGCATGTCC		GGGCAgGagg	102
113	TNFRSF10B, DR5	tumor necrosis factor receptor superfamily, 10b	NM_003842	GGGCATGTCC		GGGCAAGaCg	103
114	TNFRSF10C, DcR1	tumor necrosis factor receptor superfamily, 10c	NM_003841	GGGCATGTCC		GGGCAGGACG	104
115	TNFRSF10D, DcR2	tumor necrosis factor receptor superfamily, 10d	NM_003840	GGGCATGTCT		GGGCAGGACG	104
116	TP53, p53	tumor protein p53 (Li-Fraumeni syndrome)	NM_000546	TTACTTGCCC		TTACTTGTCa	105

117	TP53i3, Pig3	tumor protein p53 inducible protein 3	NM_004881	large	cluster	site	106
118	TP53INP1	tumor protein p53 inducible nuclear protein 1	NM_033285	GAACCTGggg		GAACATGTTT	107
119	TP63, TP73L	tumor protein p63, p73-like Delta N variant	AF075433	TAACCTGTTA	ttg	AAACATGCTC	108
120	TP73, p73	tumor protein p73	NM_005427	GtACTTGCCg	tccgggga	GAACCTGCag	109
120	TP73, p73	tumor protein p73	NM_005427	GAACCTGCag	agtaagctgga	GAGCTTGaaT	109
121	TP73:Delta	tumor protein p73 Delta N variant	AY040827	GGGCAAGCT	gaggcctgcccc	GGACTTGGAT	110
122	TRIAP1, p53CSV	TP53 regulated inhibitor of apoptosis 1	NM_016399	CTTCATGTCC		GTGCATGCCT	111
123	TRIM22, Staf50	tripartite motif-containing 22	NM_006074	TGACATGTCT		AGGCATGTAG	112
124	TRPM2	transient receptor potential cation channel, M2	NM_003307	GGCCTTGCCCT	tgctc	AGGCCTGCCT	4
124	TRPM2	transient receptor potential cation channel, M2	NM_003307	GAGCAGGTCT	gacctgctccca	GGGCCTGCCT	4
124	TRPM2	transient receptor potential cation channel, M2	NM_003307	TGCCTTGCTC		AGGCCTGCCT	4
125	TSC2	tuberous sclerosis 2	NM_000548	TAACAAGCTC	g	GGGCTAGCCC	113
125	TSC2	tuberous sclerosis 2	NM_000548	AGGCTAGTCT	gaaactctgggc	TGACGTGAC	113
125	TSC2	tuberous sclerosis 2	NM_000548	GGGCATGGTG		GCACATGCCT	113
126	TYRP1, TRP-1	tyrosinase-related protein 1	NM_000550	CGCCTAGTTT	gggt	GAGCAGATT	114
126	TYRP1, TRP-1	tyrosinase-related protein 1	NM_000550	GAGCAGATT	tgggattaattatc	AGGCAGCAA	114
126	TYRP1, TRP-1	tyrosinase-related protein 1	NM_000550	CCACATGCAC	t	TAACAGTTC	114
126	TYRP1, TRP-1	tyrosinase-related protein 1	NM_000550	AGACCAGCCC	cc	CGCCTAGTTT	114
126	TYRP1, TRP-1	tyrosinase-related protein 1	NM_000550	AGGCAGCAA	t	CCACATGCAC	114
127	UBD, FAT10	ubiquitin D	NM_006398	AGGCATGCTC		AGTGCCGTGG	115
128	VCAN, CSPG2	versican	NM_004385	AGACTTGCC	a	CAGACAAGTCC	116
129	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor	NM_000376	TAACTAGTTT		GAACAAGTTG	117
129	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor	NM_000376	AGGTTAGATG	tac	TAACTAGTTT	117

*This table provides the gene names, the accession numbers and the DNA response elements (REs) of experimentally validated p53-regulated genes. The REs typically consist of two half sites separated by a variable length spacer. Exceptional cases consist of only one apparent half site. The REs that consist of many (>4) half sites are annotated as 'large cluster sites', and as such, are too large to include in the space provided.

References

1. Johnson, R. A., Ince, T. A. & Scotto, K. W. Transcriptional repression by p53 through direct binding to a novel DNA element. *J Biol Chem* 276, 27716–27720 (2001).
2. Wang, L. et al. Analyses of p53 Target Genes in the Human Genome by Bioinformatic and Microarray Approaches. *J. Biol. Chem.* 276, 43604–43610 (2001).
3. Wu, M. et al. AMID is a p53-inducible gene downregulated in tumors. *Oncogene* 23, 6815–6819 (2004).
4. Mirza, A. et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. *Oncogene* 22, 3645–3654 (2003).
5. Robles, A. I., Bemmels, N. A., Foraker, A. B. & Harris, C. C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. *Cancer Res* 61, 6660–6664 (2001).
6. Jaiswal, A. S. & Narayan, S. p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. *J Biol Chem* 276, 18193–18199 (2001).
7. Ma, K. et al. E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53. *Mol Cancer Res* 1, 438–444 (2003).
8. Zhang, C. et al. Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. *Biochem Biophys Res Commun* 297, 1302–1310 (2002).
9. Soussi, T. p53 alterations in human cancer: more questions than answers. *Oncogene* 26, 2145–2156 (2007).
10. Thornborrow, E. C., Patel, S., Mastropietro, A. E., Schwartzfarb, E. M. & Manfredi, J. J. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine bax genes. *Oncogene* 21, 990–999 (2002).
11. Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. *Mol Cell* 7, 683–694 (2001).
12. Miled, C., Pontoglio, M., Garbay, S., Yaniv, M. & Weitzman, J. B. A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. *Cancer Res* 65, 5096–5104 (2005).
13. Margalit, O. et al. BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. *Blood* 107, 1599–1607 (2006).
14. Saifudeen, Z., Du, H., Dipp, S. & El-Dahr, S. S. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. *J Biol Chem* 275, 15557–15562 (2000).
15. Sax, J. K. et al. BID regulation by p53 contributes to chemosensitivity. *Nat Cell Biol* 4, 842–849 (2002).
16. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. *J Biol Chem* 277, 3247–3257 (2002).
17. Fei, P. et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. *Cancer Cell* 6, 597–609 (2004).
18. Duriez, C. et al. The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. *Gene* 282, 207–214 (2002).
19. Jen, K.-Y. & Cheung, V. G. Identification of novel p53 target genes in ionizing radiation response. *Cancer Res* 65, 7666–7673 (2005).
20. Saigusa, K. et al. RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest. *Oncogene* 26, 1110–1121 (2007).
21. Gupta, S., Radha, V., Furukawa, Y. & Swarup, G. Direct transcriptional activation of human caspase-1 by tumor suppressor p53. *J Biol Chem* 276, 10585–10588 (2001).
22. Rikhof, B., Corn, P. G. & El-Deiry, W. S. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. *Cancer Biol Ther* 2, 707–712 (2003).
23. MacLachlan, T. K. & El-Deiry, W. S. Apoptotic threshold is lowered by p53 transactivation of caspase-6. *Proc Natl Acad Sci U S A* 99, 9492–9497 (2002).
24. Bist, A., Fielding, C. J. & Fielding, P. E. p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. *Biochemistry* 39, 1966–1972 (2000).
25. Endo, Y., Fujita, T., Tamura, K., Tsuruga, H. & Nojima, H. Structure and chromosomal assignment of the human cyclin G gene. *Genomics* 38, 92–95 (1996).
26. Mori, T. et al. Cyclin K as a Direct Transcriptional Target of the p53 Tumor Suppressor. *Neoplasia* 4, 268–274 (2002).
27. Mashimo, T. et al. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. *Proc Natl Acad Sci U S A* 95, 11307–11311 (1998).
28. Clair, S. S. et al. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. *Mol Cell* 16, 725–736 (2004).
29. el Deiry, W. S. et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. *Cancer Res* 55, 2910–2919 (1995).
30. Saramki, A., Banwell, C. M., Campbell, M. J. & Carlberg, C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. *Nucleic Acids Res* 34, 543–554 (2006).
31. Yu, X. & Levine, A. J. p53 regulation of the genes in the endosome compartment and autophagy. 2007.

32. Wu, G. S., Saftig, P., Peters, C. & El-Deiry, W. S. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. *Oncogene* 16, 2177–2183 (1998).
33. Shiraishi, K. *et al.* Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. *Cancer Res* 60, 3722–3726 (2000).
34. Tan, T. & Chu, G. p53 Binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. *Mol Cell Biol* 22, 3247–3254 (2002).
35. Ellisen, L. W. *et al.* REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. *Mol Cell* 10, 995–1005 (2002).
36. Sakuma, S. *et al.* Receptor protein tyrosine kinase DDR is up-regulated by p53 protein. *FEBS Lett* 398, 165–169 (1996).
37. Shou, J. *et al.* Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. *Oncogene* 21, 878–889 (2002).
38. Peterson, E. J., Bgler, O. & Taylor, S. M. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. *Cancer Res* 63, 6579–6582 (2003).
39. Li, M., Zhou, J.-Y., Ge, Y., Matherly, L. H. & Wu, G. S. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. *J Biol Chem* 278, 41059–41068 (2003).
40. Ueda, K., Arakawa, H. & Nakamura, Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. *Oncogene* 22, 5586–5591 (2003).
41. Hearnes, J. M. *et al.* Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. *Mol Cell Biol* 25, 10148–10158 (2005).
42. Kato, M. V., Sato, H., Nagayoshi, M. & Ikawa, Y. Upregulation of the elongation factor-1alpha gene by p53 in association with death of an erythroleukemic cell line. *Blood* 90, 1373–1378 (1997).
43. Ludes-Meyers, J. H. *et al.* Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. *Mol Cell Biol* 16, 6009–6019 (1996).
44. Dohn, M., Jiang, J. & Chen, X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. *Oncogene* 20, 6503–6515 (2001).
45. Liebetrau, W., Budde, A., Savoia, A., Grummt, F. & Hoehn, H. p53 activates Fanconi anemia group C gene expression. *Hum Mol Genet* 6, 277–283 (1997).
46. Miller, M. *et al.* p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. *J Exp Med* 188, 2033–2045 (1998).
47. Liu, G. & Chen, X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. *Oncogene* 21, 7195–7204 (2002).
48. Smith, M. L. *et al.* Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. *Science* 266, 1376–1380 (1994).
49. Tan, M., Wang, Y., Guan, K. & Sun, Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. *Proc Natl Acad Sci U S A* 97, 109–114 (2000).
50. Kannan, K., Amariglio, N., Rechavi, G. & Givol, D. Profile of gene expression regulated by induced p53: connection to the TGF-beta family. *FEBS Lett* 470, 77–82 (2000).
51. Kimura, Y. *et al.* Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. *Genomics* 41, 477–480 (1997).
52. Ori, A. *et al.* p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. *EMBO J* 17, 544–553 (1998).
53. Feng, Z. *et al.* p53 tumor suppressor protein regulates the levels of huntingtin gene expression. *Oncogene* 25, 1–7 (2006).
54. Metcalfe, A. M., Dixon, R. M. & Radda, G. K. Wild-type but not mutant p53 activates the hepatocyte growth factor/scatter factor promoter. *Nucleic Acids Res* 25, 983–986 (1997).
55. Britschgi, C. *et al.* Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. *Oncogene* 25, 2030–2039 (2006).
56. Deguin-Chambon, V., Vacher, M., Jullien, M., May, E. & Bourdon, J. C. Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis. *Oncogene* 19, 5831–5841 (2000).
57. Zhang, Y. *et al.* Repression of hsp90beta gene by p53 in UV irradiation induced apoptosis of Jurkat cells. *J Biol Chem* 279, 42545–42551 (2004).
58. Ng, C.-C., Arakawa, H., Fukuda, S., Kondoh, H. & Nakamura, Y. p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. *Oncogene* 22, 4449–4458 (2003).
59. Im, H.-J., Pittelkow, M. R. & Kumar, R. Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1. *J Biol Chem* 277, 14612–14621 (2002).
60. Buckbinder, L. *et al.* Induction of the growth inhibitor IGF-binding protein 3 by p53. *Nature* 377, 646–649 (1995).
61. Mori, T. *et al.* Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. *Oncogene* 21, 2914–2918 (2002).
62. Mukhopadhyay, T. & Roth, J. A. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines. *Anticancer Res* 16, 105–112 (1996).

63. Raimond, J., Rouleux, F., Monsigny, M. & Legrand, A. The second intron of the human galectin-3 gene has a strong promoter activity down-regulated by p53. *FEBS Lett* 363, 165–169 (1995).
64. Hu, W., Feng, Z., Teresky, A. & Levine, A. J. p53 regulates maternal reproduction through LIF. *Nature* 450, 721–724 (2007).
65. Lin, Y., Ma, W. & Benchimol, S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. *Nat Genet* 26, 122–127 (2000).
66. Chun, A. C. S. & Jin, D.-Y. Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. *J Biol Chem* 278, 37439–37450 (2003).
67. Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y. & Oren, M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. *Nucleic Acids Res* 23, 2584–2592 (1995).
68. Seol, D. W., Chen, Q., Smith, M. L. & Zarnegar, R. Regulation of the c-met proto-oncogene promoter by p53. *J Biol Chem* 274, 3565–3572 (1999).
69. Chen, J. & Sadowski, I. Identification of the mismatch repair genes PMS2 and MLH1 as p53 target genes by using serial analysis of binding elements. *Proc Natl Acad Sci U S A* 102, 4813–4818 (2005).
70. Bian, J. & Sun, Y. Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. *Mol Cell Biol* 17, 6330–6338 (1997).
71. Warnick, C. T., Dabbas, B., Ford, C. D. & Strait, K. A. Identification of a p53 response element in the promoter region of the hMSH2 gene required for expression in A2780 ovarian cancer cells. *J Biol Chem* 276, 27363–27370 (2001).
72. Scherer, S. J. et al. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. *J Biol Chem* 275, 37469–37473 (2000).
73. Stein, S. et al. NDRG1 is necessary for p53-dependent apoptosis. *J Biol Chem* 279, 48930–48940 (2004).
74. Sadasivam, S. et al. Caspase-1 activator Ipaf is a p53-inducible gene involved in apoptosis. *Oncogene* 24, 627–636 (2005).
75. Mortensen, K., Skouv, J., Hougaard, D. M. & Larsson, L. I. Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53. *J Biol Chem* 274, 37679–37684 (1999).
76. Urano, T. et al. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. *Cancer Res* 57, 3281–3287 (1997).
77. Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. *Cell* 102, 849–862 (2000).
78. Zhu, J. & Chen, X. MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M. *Mol Cell Biol* 20, 5602–5618 (2000).
79. Morris, G. F., Bischoff, J. R. & Mathews, M. B. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. *Proc Natl Acad Sci U S A* 93, 895–899 (1996).
80. Reczek, E. E., Flores, E. R., Tsay, A. S., Attardi, L. D. & Jacks, T. Multiple response elements and differential p53 binding control Perp expression during apoptosis. *Mol Cancer Res* 1, 1048–1057 (2003).
81. Rozenfeld-Granot, G. et al. A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. *Oncogene* 21, 1469–1476 (2002).
82. Burns, T. F., Fei, P., Scata, K. A., Dicker, D. T. & El-Deiry, W. S. Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. *Mol Cell Biol* 23, 5556–5571 (2003).
83. de Stanchina, E. et al. PML is a direct p53 target that modulates p53 effector functions. *Mol Cell* 13, 523–535 (2004).
84. Yan, J. et al. BLIMP1 regulates cell growth through repression of p53 transcription. *Proc Natl Acad Sci U S A* 104, 1841–1846 (2007).
85. Stambolic, V. et al. Regulation of PTEN transcription by p53. *Mol Cell* 8, 317–325 (2001).
86. Golubovskaya, V., Kaur, A. & Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. *Biochim Biophys Acta* 1678, 111–125 (2004).
87. Ohtsuka, T. et al. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. *Nat Cell Biol* 6, 121–128 (2004).
88. Shiio, Y., Yamamoto, T. & Yamaguchi, N. Negative regulation of Rb expression by the p53 gene product. *Proc Natl Acad Sci U S A* 89, 5206–5210 (1992).
89. Dornan, D. et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. *Nature* 429, 86–92 (2004).
90. Tanaka, H. et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature* 404, 42–49 (2000).
91. Tan, M., Heizmann, C. W., Guan, K., Schafer, B. W. & Sun, Y. Transcriptional activation of the human S100A2 promoter by wild-type p53. *FEBS Lett* 445, 265–268 (1999).
92. Han, H. J., Tokino, T. & Nakamura, Y. CSR, a scavenger receptor-like protein with a protective role against cellular damage caused by UV irradiation and oxidative stress. *Hum Mol Genet* 7, 1039–1046 (1998).
93. Adachi, K. et al. Identification of SCN3B as a novel p53-inducible proapoptotic gene. *Oncogene* 23, 7791–7798 (2004).
94. Zou, Z. et al. p53 regulates the expression of the tumor suppressor gene maspin. *J Biol Chem* 275, 6051–6054 (2000).

95. Kunz, C., Pebler, S., Otte, J. & von der Ahe, D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. *Nucleic Acids Res* 23, 3710–3717 (1995).
96. Velasco-Miguel, S. et al. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. *Oncogene* 18, 127–137 (1999).
97. Hermeking, H. et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. *Mol Cell* 1, 3–11 (1997).
98. Nagy, N. et al. Wild-type p53 activates SAP expression in lymphoid cells. *Oncogene* 23, 8563–8570 (2004).
99. Passer, B. J. et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. *Proc Natl Acad Sci U S A* 100, 2284–2289 (2003).
100. Herzer, K. et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. *J Virol* 77, 8299–8309 (2003).
101. Shin, T. H., Paterson, A. J. & Kudlow, J. E. p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. *Mol Cell Biol* 15, 4694–4701 (1995).
102. Liu, X., Yue, P., Khuri, F. R. & Sun, S.-Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. *Cancer Res* 64, 5078–5083 (2004). URL
103. Takimoto, R. & El-Deiry, W. S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. *Oncogene* 19, 1735–1743 (2000).
104. Liu, X., Yue, P., Khuri, F. R. & Sun, S.-Y. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. *Cancer Res* 65, 9169–9175 (2005).
105. Benoit, V. et al. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter. *Oncogene* 19, 4787–4794 (2000).
106. Contente, A., Dittmer, A., Koch, M. C., Roth, J. & Dobbstein, M. A polymorphic microsatellite that mediates induction of PIG3 by p53. *Nat Genet* 30, 315–320 (2002).
107. Okamura, S. et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. *Mol Cell* 8, 85–94 (2001).
108. Harmes, D. C. et al. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. *Oncogene* 22, 7607–7616 (2003).
109. Chen, X., Zheng, Y., Zhu, J., Jiang, J. & Wang, J. p73 is transcriptionally regulated by DNA damage, p53, and p73. *Oncogene* 20, 769–774 (2001).
110. Nakagawa, T. et al. Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. *Mol Cell Biol* 22, 2575–2585 (2002).
111. Park, W.-R. & Nakamura, Y. p53CSV, a novel p53-inducible gene involved in the p53-dependent cell-survival pathway. *Cancer Res* 65, 1197–1206 (2005).
112. Obad, S. et al. Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. *Oncogene* 23, 4050–4059 (2004).
113. Feng, Z. et al. The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. *Cancer Res* 67, 3043–3053 (2007).
114. Nylander, K. et al. Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response. *J Pathol* 190, 39–46 (2000).
115. Zhang, D. W., Jeang, K.-T. & Lee, C. G. L. p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers. *Oncogene* 25, 2318–2327 (2006).
116. Yoon, H. et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. *Proc Natl Acad Sci U S A* 99, 15632–15637 (2002).
117. Maruyama, R. et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. *Cancer Res* 66, 4574–4583 (2006).